Oncostatin-M-Reactive Pericytes Aggravate Blood-Brain Barrier Dysfunction by Activating JAK/STAT3 Signaling In Vitro
Overview
Authors
Affiliations
Oncostatin M (OSM) is a cytokine of the interleukin (IL)-6 family members. It induces blood-brain barrier (BBB) dysfunction by activating Janus-activated kinase (JAK) and signal transducer and activator of transcription (STAT) 3 pathways in brain endothelial cells. Brain pericytes located around microvessels are one of the BBB constituents. Pericytes work as a boundary surface between the blood circulation and brain parenchyma, and their functions are altered under pathophysiological conditions, leading to BBB dysregulation. However, it remains unknown whether pericytes are associated with OSM-induced BBB dysfunction. We demonstrated that pericyte exposure to OSM (100 ng/mL) elevated phosphorylation of STAT3, a main OSM signaling pathway, and that pericytes expressed OSM receptors (OSMRs) including OSMRβ and glycoprotein 130. These results suggest that pericytes are able to respond to OSM. To determine the effects of OSM-reactive pericytes on BBB functions, rat brain endothelial cell (RBEC) monolayers were cultured with OSM-treated pericytes. The presence of pericytes exposed to 100 ng/mL of OSM for 48 h aggravated both the elevated permeability to sodium fluorescein and the lowered transendothelial electrical resistance which were induced by OSM in RBECs. This OSM-reactive pericyte-induced aggravation of lowered RBEC barrier function was reversed by ruxolitinib, a JAK inhibitor. These findings suggest that activated JAK/STAT3 signaling in pericytes contributes to OSM-produced BBB breakdown. Thus, OSM-reactive pericytes may have to be considered a characteristic machinery in the formation and progression of BBB breakdown under pathological conditions associated with increased OSM levels.
Blood-brain barrier permeability increases with the differentiation of glioblastoma cells in vitro.
Digiovanni S, Lorenzati M, Bianciotto O, Godel M, Fontana S, Akman M Fluids Barriers CNS. 2024; 21(1):89.
PMID: 39487455 PMC: 11529439. DOI: 10.1186/s12987-024-00590-0.
Yang H, Liu W, Gao T, Liu Q, Zhang M, Liu Y Front Immunol. 2024; 15:1438645.
PMID: 39315097 PMC: 11416947. DOI: 10.3389/fimmu.2024.1438645.
Characterization of Proteome Changes in Aged and Collagen VI-Deficient Human Pericyte Cultures.
Moriggi M, Torretta E, Cescon M, Russo L, Gregorio I, Braghetta P Int J Mol Sci. 2024; 25(13).
PMID: 39000224 PMC: 11241165. DOI: 10.3390/ijms25137118.
Ricciardelli A, Robledo A, Fish J, Kan P, Harris T, Wythe J Biomedicines. 2023; 11(11).
PMID: 38001877 PMC: 10669898. DOI: 10.3390/biomedicines11112876.
The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf C, Pruett C, Lighter D, Jorcyk C Front Immunol. 2023; 14:1239732.
PMID: 37841259 PMC: 10570509. DOI: 10.3389/fimmu.2023.1239732.